News:Clinical trials
Read the latest news about clinical trials on Alzheimer's prevention with the participation of the Barcelonaβeta Brain Research Center (BBRC).
The BBRC, participating center in a new clinical trial
The international study Skyline plans to enroll 1.200 participants worldwide to assess a new treatment against Alzheimer's disease.
The United States approves the commercialization of a drug that could slow down Alzheimer's disease
The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.
The FDA accepts license application for aducanumab, the first possible disease modifying drug for Alzheimer’s
Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.
World-Wide FINGERS: Spain is part of the first global initiative for prevention of dementia and Alzheimer´s disease
BBRC participates with the PENSA study
BBRC and IMIM kick off a clinical trial of dementia prevention on people with memory problems
The PENSA Study will combine a program of interventions in lifestyle habits and the ingestion of a preparation based on a component from the green tea
Dr. José Luis Molinuevo on the closure of Biogen's clinical trials
The scientific director of BBRC's Alzheimer’s Prevention Program suggests trying a new aproach in order to keep working with Aducanumab
BBRC researchers participate in the 11th Clinical Trials on Alzheimer’s disease
CTAD conference took place in Barcelona, from the 24th to the 27th of October.
Barcelonaβeta Brain Research Center brings to Spain clinical trials in healthy people to prevent Alzheimer’s disease
The studies will analyze the efficacy of various pharmacological treatments designed to act before the manifestation of the clinical symptoms of the disease.
